Navigation Links
Further doubt cast on virus link to chronic fatigue
Date:2/16/2010

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (CFS). Their study, published in BioMed Central's open access journal Retrovirology, calls into question a potential link described late last year by an American research team.

Kate Bishop from the MRC National Institute for Medical Research worked with a team of researchers to test blood and serum samples from 170 CFS patients and 395 healthy controls, using quantitative PCR and a virus neutralization assay. She said, "No association between XMRV infection and CFS was observed in the samples tested, either by PCR or serological methodologies. Our findings therefore appear inconsistent with the previous report that isolated XMRV from the blood cells of CFS patients. We are confident that, although we were unable to replicate the detection, our PCR assay is more sensitive than the earlier method and possessed the necessary sensitivity to detect XMRV had it been present".

Bishop and her colleagues point out that CFS likely encompasses a range of diseases, and it is still possible that some of them might be associated with XMRV infection. They say, "There has been much discussion and controversy amongst CFS researchers and patients alike, which highlights the need for additional investigations in this area. Following our findings, it would seem a prudent next step for subsequent studies to compare samples and protocols between different laboratories around the world".

The findings of this Retrovirology study are supported by results from a recently published work from Imperial College London that also found no proof that XMRV infection is associated with CFS.


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-319-22165
BioMed Central
Source:Eurekalert

Page: 1

Related biology news :

1. Further development of Water Framework Directive necessary
2. Further breakthroughs for breast cancer patients
3. Worlds largest investor coalition seeks further disclosure on climate change and shareholder value
4. Immunosuppressant further linked to birth defects
5. New study casts further doubt on risk of death from higher salt intake
6. New CITES quotas allow more caviar export, further jeopardize endangered sturgeon
7. UNC, Caltech research finds further evidence for genetic contribution to autism
8. New book further supports controversial theory of Man the Hunted
9. Characterization of grapevine transposons furthers understanding of in vino variety
10. New study provides further evidence that apple juice can delay onset of Alzheimers disease
11. Researcher garners major award from NIH for further exploration into the mechanisms of obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... -- AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a ... a majority-owned subsidiary of Intrexon Corporation (NYSE: ... of its common shares on the NASDAQ Stock Market ... "AquaBounty,s listing on NASDAQ represents an important milestone for ... U.S. markets as we advance plans for commercial production ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology: